ANTITUMOR EFFICACY OF LIPOSOMAL DOXORUBICIN HYDROCHLORIDE IN COMBINATION WITH TAMOXIFEN. EXPERIMENTAL STUDY

In this paper we evaluated the effectiveness of adjuvant chemotherapy in animals (n=30), which created a model of cancerogenesis. We created 3 equal studies: the 1st group control (n=10) - animals were monitored without treatment; the 2nd group (n=10) - animals received adjuvant therapy with a combination of drugs: liposomal doxorubicin hydrochloride+tamoxifen;the 3rd group (n=10) - animals received adjuvant therapy in a combination of doxorubicin hydrochloride (non-liposomal)+tamoxifen. All animals were monitored for a total of 30 days. As a result, the volume of the tumor in the group of animals treated with liposomal doxorubicin hydrochloride was almost 3 times less than in the control group, and 2 times less than in the rats treated with simple doxorubicin. We also recorded a significantly lower number of lung metastases in animals of the second group compared to other groups. CONCLUSION. Treatment of Walker 256 tumors with liposomal doxorubicin showed better efficacy and safety compared to non-liposomal doxorubicin.

Authors
Inchina V.1 , Izbastyyeva M.1 , Tarasova T.1 , Ulanova T.2 , Avanesov A. 3 , Khaydar D. 3
Publisher
EUROPAISCHE WISSENSCHAFTLICHE GESELLSCHAFT EV
Number of issue
3
Language
English
Pages
22-24
Status
Published
Volume
10
Year
2020
Organizations
  • 1 Natl Res Ogarev Mordovia State Univ, Saransk, Russia
  • 2 Obninsk Inst Nucl Power Engn, Fac Med, Obninsk, Russia
  • 3 Peoples Friendship Univ Russia, RUDN Univ, Moscow, Russia
Keywords
Liposomal doxorubicin hydrochloride; adjuvant chemotherapy; breast cancer; tumor of the Walker strain; metastasis
Date of creation
20.04.2021
Date of change
20.04.2021
Short link
https://repository.rudn.ru/en/records/article/record/73134/
Share

Other records